trial

Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TPN672 Tablets Maleate in Patients With Schizophrenia

NCTId NCT05192304
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Unknown
Enrollment 62 (estimated)
Sponsored by Jiangsu Kanion Pharmaceutical Co., Ltd
Primary completion 2023-03-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Unknown
Enrollment
62 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2022-02-01
Primary completion
2023-03-01
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
TPN-672

Sponsors

Jiangsu Kanion Pharmaceutical Co., LtdLead Sponsor
Shanghai Mental Health CenterCollaborator

Investigators

2
Li Huafang, MD PhDPrincipal Investigator
Li GuanjunPrincipal Investigator

Sites

1 total
Shanghai, China

Facts & assertions

4 sourced
Enrollment
62
Phase
PHASE1
Primary Completion Date
2023-03-01
Status
UNKNOWN
relationships
The graph out of here
drug
TPN-672
drug
lead_sponsor
Jiangsu Kanion Pharmaceutical Co., Ltd
company
collaborator
Shanghai Mental Health Center
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Li Huafang, MD PhD
person
Li Guanjun
person